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SUMMARY
Otitis media (OM) accounts for 31 million physician visits annually, and is typically treated with antibiotics. Amoxicillin
is the recommended first-line treatment; appropriate antibiotic use slows the development of resistance. We analyzed insur-
ance claims from families of employees working at a single company to determine if OM treatments (1) matched published
standards; and (2) varied by patient characteristics, type of physician practice or geographic location. Persons diagnosed
with OM between 1996 and 1999 were matched to prescription drug claims for those who filled an antibiotic prescription
within 3 days of diagnosis. Physicians prescribed amoxicillin for only 31% of acute cases and 19% of recurrent cases. For
acute infections in children2 years the prescribed duration often matched the standard of 10 days, but for persons >2 years
the prescribed duration was often longer than the suggested duration of 5–7 days. For persons of all ages with recurrent
infections, the prescribed duration was often shorter than suggested (10 days versus14 days). There were only modest
variations by urban/rural location or provider type. Copyright # 2002 John Wiley & Sons, Ltd.
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INTRODUCTION
Otitis media (OM) is the single most common bacter-
ial infection diagnosed in children younger than 15
years who visit physicians on an outpatient basis.1
More than 24 million cases are seen annually in the
United States, and the number of cases has increased
substantially during the last 2 decades.2 Sixty percent
of all children have at least one office visit for acute
otitis media by age 1 year, 75% have one visit by
age 3 years, and 33% have three or more episodes
by age 3 years.3 Among adults OM also occurs fre-
quently; overall, OM accounts for 31 million physi-
cian visits annually, and results in 20–25% of all
orders for oral antibiotics prescribed yearly in the
United States.3
OM frequently recurs. Therefore, prophylatic dura-
tion of therapy is recommended for recurring OM,
usually defined as four or more episodes in a
12-month period. Since OM is a frequent complaint,
and most physicians vary in their approach to treating
OM, even small variations in diagnosis and treatment
can account for large differences in expense when
aggregated over millions of cases. The medical and
nonmedical costs of OM episodes are high: $114
and $131, respectively, for a simple episode and
$404 and $327, respectively, for a complex relapsing
episode.2
Over the last 10 years, primary OM pathogens,
Streptococcus pneumoniae and Haemophilus influen-
zae and Moraxella cataralis, have become resistant to
the majority of antibiotic drugs used in the treatment
of OM. For example, the SENTRYAntimicrobial Sur-
veillance Program (1997–1999) detected the follow-
ing rates in the US for respiratory isolates of
Streptococcus pneumoniae: 3.2% were amoxicillin-
resistant and 26.2% were cefaclor-resistant; Haemo-
philus influenzae: 31.5% were amoxicillin-resistant
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and 14.6% were trimethoprim-sulfamethoxazole
resistant; Moraxella cataralis: 0.1% were amoxicillin-
clavulanate resistant and 96.8% were clindamycin-
resistant.4
Because of the high incidence of OM, antibiotic
therapy has a large potential to increases the risk of
resistance development. In order to preserve their
effectiveness, judicious use is required.1 Treatment
guidelines are intended to reduce pressures for anti-
biotic resistance. OM is almost always diagnosed
clinically; the symptoms are frequently caused by
viruses rather than bacteria. Further, OM is often
self-limiting. Because of the high incidence and
self-limiting nature, antibiotic treatment for OM has
a large potential to increase population pressure for
the development of antibiotic resistance.5 Thus,
watchful waiting is suggested in some countries; most
published US guidelines recommend using amoxicil-
lin as the first-line antibiotic.6–16,18 The recommended
duration for treatment with amoxicillin varies by
patient characteristics.
We used insurance claims from persons treated in a
preferred provider organization in order to describe
the frequency and duration of amoxicillin prescribing
to treat OM infections; and to determine if the likeli-
hood of receiving a prescription for amoxicillin varied




The subjects of this study were employees and depen-
dents of a large Midwestern manufacturing organiza-
tion with preferred provider organization (PPO)
coverage who had (1) out-patient claims records for
a physician visit from 1996–1999; (2) a billed diagno-
sis of OM; and (3) pharmacy claim for antimicrobial
or anti-infective prescriptions filled within 3 days of
the office visit for OM. Diagnosis of OM was indi-
cated by the ICD-9 codes of 381.0, 381.3, 381.4,
381.00–381.06, 381.10 and 381.19. With the excep-
tion of 1999, all data were pulled as incurred in the
specific calendar year with a 3 month paid run-out.
The average age of the source PPO population was
38 years with a nearly equal gender distribution.
Our data included 13 511 claims with a diagnosis of
OM and a pharmacy claim filled within 3 days. We
then excluded 4881 claims (36%) where we could
not determine whether or not it was an acute or recur-
rent infection, 50 claims for topical antimicrobial
agents, two claims for antibiotics that must be admi-
nistered intravenously, and 1312 claims (9%) that had
a missing value for either the provider group, drug
name or provider zip code. This gave us a final study
population of 7266 claims.
Definition of recurrent infections
Recurrent episodes were separated from nonrecurrent
episodes since the recommended duration of therapy
differs. We defined a recurrence as four or more phy-
sician visits for OM within a 12-month period where a
pharmacy claim was filled within 3 days.7,9,11,16–19
We used 1996 data to define recurring infections in
1997. Therefore, only cases from claims filed during
1997–1999 were included in the analysis. This
ensured that the ‘first’ diagnosis recorded for the
1997 calendar year was the first infection after at least
a 12-month period in which the subjects were free of
infection.
Recommended OM treatment
Health care professionals, including the Center for
Disease Control and Prevention, Institute for Clinical
Systems Improvement and individual physicians sug-
gest oral amoxicillin as the first-line treatment for
OM.6–16,18 For uncomplicated acute infections, a 5–
7 day duration of amoxicillin is recommended. The
Drug-resistant Streptococcus pneumoniae Therapeu-
tic Working Group states, ‘In addition to excellent
pharmacokinetic and pharmacodynamic properties,
amoxicillin has a long record of safety and clinical
efficacy in treating OM, has a narrower spectrum of
activity than many of the alternative agents and is
inexpensive.’6 For children at high risk, i.e. age2
years, the recommendation is for a 10 day amoxicillin
prescription. Because dosage of the antibiotic varies
widely with each individual patient’s weight and
metabolism, and that information was not included
in these data, it will not be addressed in this study.
Recurrent OM infections are not specifically
addressed in the reviewed literature, but most litera-
ture suggests that a prophylactic duration of therapy,
i.e. 2– 4 weeks of a low dose, is needed for effective
treatment.7–10,12 For the purposes of this study, we
assumed a duration of 14 days or longer to be appro-
priate.
Type of physician practice
We grouped physician practices noted on the claims
data into five categories: family/general practice,
internal medicine, pediatrics, ear–nose–throat (ENT)
specialists, and other. Emergency room physicians
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were not included as a code on the claims data, so that
group is not considered separately.
Geographic location (urban versus rural)
To determine if a provider was located in a rural or
urban area, zip code data were correlated to 1990 cen-
sus information. If the 1990 census classified more
than 50% of the area within the zip code as urban, then
it received an urban designation for this study, other-
wise it was classified as rural.20
Statistical analysis
We described the prescriptions filled for acute and
recurrent OM by age, gender, provider type and geo-
graphic location using simple descriptive statistics.
We estimated the association of these variables with
the probability of amoxicillin being prescribed using
odds ratios with 95% Cornfield or Exact confidence
intervals. In order to simultaneously assess the impact
of gender, recurrence, age, geographic location and
provider type on prescribing amoxicillin we fit a logis-
tic regression model. Analyses were conducted using
SAS (SAS Institute, Cary, NC, version 8.2). We calcu-
lated odds ratios and their confidence intervals using
EpiInfo 2000 (Center for Disease Control and Preven-
tion, version 1.1.2).
RESULTS
The majority (96%) of the 7266 claims for OM in
1997–1999 were for acute infections (Table 1). Both
acute and recurrent infections occurred equally often
among males and females (46% males and 54%
females). Seventeen percent (17%) of the claims were
for children2 years. The majority (47%) of the
claims were filled for patients who saw a family/gen-
eral practitioner (Table 1). Otherwise there was a large
variation in the physician’s specialties. For each cate-
gory of claim, over 85% of those cases lived in an
urban area (Table 1).
Amoxicillin, the recommended first-line OM ther-
apy, was prescribed for only 31% of persons with acute
OM and 19% of those with recurring OM [Figures 1(a)
and (b)]. The remainder were prescribed a wide variety
of antibiotics. Eighty-two percent (82%) of acute OM
in children 2 years was prescribed the recommended
10 day duration of therapy of amoxicillin, and 18% of
recurrent OM in children 2 years was prescribed the
recommended 14 or more days of therapy of amoxicil-
lin (Table 2). For persons>2 years, 8% of acute OM
was prescribed the recommended 5–7 day duration
of therapy of amoxicillin, and 7% of recurrent OM
was prescribed the recommended 14 or more days of
therapy of amoxicillin (Table 2).
After fitting a logistic regression model including
gender, recurrence, age, geographic location and pro-
vider type, gender was not associated with amoxicillin
prescription. Persons with recurrence, younger ages
and seen at Internal Medicine or ENT provider (using
Family Practitioners as the reference group) were sig-
nificantly less likely to be prescribed amoxicillin,
while those living in urban areas were more likely
(Table 3).
Table 1. Characteristics of persons with acute and recurrent otitis media filling antibiotic prescriptions within 3 days of diagnosis, and
percent of claims for amoxicillin (7266 claims from persons or dependents working at a single company, receiving care from a preferred
provider organization, 1997–1999)
Acute OM (N¼ 6997) Recurrent (N¼ 269)
N with % claims for N with % claims for
Characteristic characteristic amoxicillin characteristic amoxicillin
Age
42 years old 1107 39 146 16
>2 years old 5890 29 123 23
Gender
Female 3758 30 134 18
Male 3239 32 135 20
Provider type
Family practice 3367 31 75 23
Internal medicine 607 24 6 0
Pediatrics 1717 39 143 17
Ear, nose and throat 1107 21 43 21
Other 199 36 2 50
Geographic location
Urban 6095 31 242 19
Rural 902 28 27 15
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Figure 1. (a) Percent distribution of antibiotic therapies prescribed to treat acute otitis media and filled within 3 days of physician visit
(6997 claims from persons or dependents, of all ages, of a single company, receiving care from a preferred provider organization, 1997–
1999). (b) Percent distribution of antibiotic therapies prescribed to treat recurrent otitis media and filled within 3 days of physician visit (269
claims from persons or dependents, of all ages, of a single company, receiving care from a preferred provider organization, 1997–1999)
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DISCUSSION
Physician prescribing patterns have a major impact on
the development of antibiotic resistance.6 Unlike dis-
eases where lengthy treatment leads to development
of individual resistance, e.g. tuberculosis, common
OM therapies are more likely to lead to the develop-
ment of resistance on a population level. We sought to
determine if physicians were prescribing amoxicillin,
the recommended first-line antibiotics for treatment of
OM.6–16,18 In general, most physicians serving the
study population did not do so.
Our finding is consistent with prescribing for OM in
a pediatric Medicaid population.21 Amoxicillin was
most frequently prescribed for a new OM episode,
but cephalosporins were prescribed to at least one
child at an index visit by 55% of the physicians.21
Further, more expensive antibiotics were not asso-
ciated with a better outcome. Our finding is also con-
sistent with a NAMCS review of antibiotic prescribing
from 1980–1992, among children under 15 years of
age diagnosed with OM. That study observed an
increasing trend for prescribing amoxicillin and
cephalosporins and no trend for prescribing trimetho-
prim-sulfmethaxazole or erythromycins.22
Physicians take into account patient history in mak-
ing a determination of what antibiotic to prescribe, for
which we had no information, such as (1) drug aller-
gies, (2) drug intolerance, (3) poor compliance
because of taste or dosing schedule, (4) suspected
resistant pathogens or (5) prior treatment failure.
However, only 1–10% of the US population is allergic
Table 2. Percent distribution of duration of therapy of amoxicillin prescribed for otitis media by recurrance and age group (7266 claims
from persons or dependents of a single company, receiving care from a preferred provider organization, 1997–1999). The optimal durations
(boldface) for children<2 years with acute infections is 10 days, and with recurrent infections 14þ days. The optimal durations (boldface)
for persons>2 years with acute infections is 5–7 days, and with recurrent infections 14þ days
Children<2 years Persons>2 years
Duration of therapy Acute Recurrent Acute Recurrent
prescribed (N¼ 433) (N¼ 23) (N¼ 1710) (N¼ 28)
(in days) % claims for % claims for % claims for % claims for
amoxicillin amoxicillin amoxicillin amoxicillin
44 0 0 0.5 0.0
5 1.6 0.0 1.2 3.6
6 0.2 0.0 0.5 0.0
7 1.6 4.4 6.4 3.6
8 0.5 0.0 0.9 3.6
9 0.0 0.0 0.3 0.0
10 82.2 78.2 82.6 78.6
11 1.4 0.0 0.4 0.0
12 1.2 0.0 0.2 0.0
13 3.0 0.0 0.4 3.6
14 3.7 4.4 2.1 0.0
15 1.4 0.0 1.4 0.0
16þ 3.2 13.1 3.2 7.1
Table 3. Logistic regression model predicting receiving and filling a prescription for amoxicillin among persons with acute and recurrent
otitis media filling antibiotic prescriptions within 3 days of diagnosis (7266 claims from persons or dependents working at a single company,
receiving care from a preferred provider organization, 1997–1999)
Variable Odds ratio (95% CI) Pr>Chi-square
Female 0.96 (0.86–1.06) 0.413
Recurring OM 0.41 (0.30–0.56) <0.0001
Age of patient (in years) 0.98 (0.98–0.99) <0.0001
Urban versus rural residence 1.24 (1.05–1.45) 0.009
Specialty of treating physician
Internal medicine 0.73 (0.60–0.90) 0.003
Pediatrics 0.93 (0.81–1.07) 0.290
Ear, nose and throat 0.54 (0.46–0.63) <0.0001
Other 1.12 (0.83–1.52) 0.457
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to penicillin or other -lactams.23 Further, even
among children attending day care, at highest risk of
both otitis media and antibiotic resistance, amoxicillin
resistance among Haemophilus influenzae and Strep-
tococcus pneumoniae does not exceed one-third.24
Thus, it seems unlikely that more than half of all
OM patients have some other factor that would pre-
clude amoxicillin use. Study participants were all
members of a single PPO that has minimal prescrip-
tion co-pays, maximizing the possibility that a pre-
scription is filled. Some may have been treated by
free samples or information or not given an antibiotic
at all. We have no information on this group. Since the
physicians in our sample do not exclusively see PPO
patients we can assume that the same physician would
use the same decision-making algorithm for treating
all of his/her other patients. This would make our
study most likely generalizable to physicians in the
Midwest.
Because we linked insurance claims for OM to anti-
biotic prescriptions we cannot be certain that the anti-
biotic was in fact prescribed for the OM. To minimize
this potential we included only persons filling pre-
scriptions within 3 days of the office visit, and
excluded all cases where the prescribed antibiotic
was one that could not be given in an out-patient set-
ting or that is used topically. Bacterial OM is difficult
to accurately diagnose25 and is difficult to distinguish
from OM caused by viral agents. Short of requiring
culture—which is not a standard practice—we can-
not be certain of the diagnosis. We based our diagno-
sis on billing codes and have made no verification of
the diagnosis. Thus, some misclassification in diagno-
sis could have occurred both via the physician’s mis-
diagnosis and because OM was the stated billing code
for convenience or other reasons.
Patient compliance is a major issue that can lead to
antibiotic resistance. Duration of therapy prescribed
does not necessarily reflect how long the therapy
was used. However, as our focus was on what the phy-
sician prescribed rather than on compliance, this is not
a limitation of our study. We acknowledge that studies
on the impact of emerging resistance attributed to the
use of different classes of antimicrobials and different
durations are less clear, and, therefore, the ‘ideal’ pre-
scription is controversial.
OM pathogens are major causes of other, more
invasive, diseases such as meningitis.26 Because of
this, preserving their antibiotic sensitivities is a prior-
ity. In our study population antibiotics used to treat
OM were fairly uniformly prescribed. We did not
see strong differences by speciality or geographic
location suggesting that while prescribing habits
may not be following first-line suggested therapy, they
are at least stable enough to determine if a change in
habit will alter the levels of drug resistance in a com-
munity.
In conclusion, while amoxicillin was the most com-
monly prescribed antibiotic for OM, it represents a
much lower percentage than might be anticipated
based on published guidelines. This might be reme-
died by educating both physicians and patients on
the proper use of antibiotics for OM. As resistance
patterns may change rapidly, local surveillance for
resistance to common bacterial pathogens would
facilitate appropriate treatment and provide needed
information for keeping guidelines current.
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